WO2002026724A1 - Cyclized benzamide neurokinin antagonists for use in therapy - Google Patents
Cyclized benzamide neurokinin antagonists for use in therapy Download PDFInfo
- Publication number
- WO2002026724A1 WO2002026724A1 PCT/SE2001/002100 SE0102100W WO0226724A1 WO 2002026724 A1 WO2002026724 A1 WO 2002026724A1 SE 0102100 W SE0102100 W SE 0102100W WO 0226724 A1 WO0226724 A1 WO 0226724A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- cyano
- disorders
- compound according
- alkylcarbamoyl
- Prior art date
Links
- 0 C*C***c1c(C([N+](C)CC(CC(C)(*)*)c2ccccc2)=O)c(*)c(*)c(*)c1* Chemical compound C*C***c1c(C([N+](C)CC(CC(C)(*)*)c2ccccc2)=O)c(*)c(*)c(*)c1* 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/22—Eight-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- X and X are independently hydrogen or halo, provided that at least one of X or X is halo.
- X 1 and X 2 are both chloro.
- Ph-X 1 ⁇ 2 is 3,4- dichlorophenyl.
- R lb is H and R lc is H. And in another embodiment, R l is
- Another aspect of the invention involves a pharmaceutical composition comprising a therapeutically effective amound of a compound of formula la.
- Another aspect of the invention involves a method of treating major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, emesis, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility,
- basic nitrogen- containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides like benzyl bromide and others.
- Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.
- composition of this invention may also contain, or be co-administered (simultaneously or sequentially) with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.
- compositions of this invention will normally be administered to humans so that, for example, a daily dose of 0.01 to 25 mg/kg body weight (and preferably of 0.1 to 5 mg/kg body weight) is received.
- This daily dose may be given in divided doses as necessary, the precise amount of the compound received and the route of administration depending on the weight, age and sex of the patient being treated and on the particular disease
- unit dosage forms will contain about 1 mg to 500 mg of a compound of this invention.
- a tablet or capsule for oral administration may conveniently contain up to 250 mg (and typically 5 to 100 mg) of a compound- of the formula (I) or a pharmaceutically acceptable salt thereof.
- a compound of the formula (I) or a pharmaceutically acceptable salt thereof may be administered in a daily dosage range of 5 to 100 mg, in a single dose or divided into two to lour daily doses.
- a sterile solution or suspension containing up to 10% w/w (and typically 5% w/w) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof may be used.
- the present invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof for use in a method of therapeutic treatment of the human or animal body.
- the present invention provides a method of treating a disease condition wherein antagonism of the NKi receptor is beneficial which comprises administering to a warm-blooded animal an effective amount of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof.
- the present invention also provides the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for use in a disease condition wherein antagonism of the NKi receptor is beneficial.
- the compounds of the formula (I) and their pharmaceutically acceptable salts may be made by processes as described and exemplified herein and by processes similar thereto and by processes known in the chemical art. If not commercially available, starting materials for these processes may be made by procedures which are selected from the chemical art using techniques which are similar or analogous to the synthesis of known compounds.
- Test A The ability of a compound of the invention to antagonize the binding of SP at the NKi receptor may be demonstrated using an assay using the human NKi receptor expressed in
- Magnesium iodide etherate was prepared from magnesium metal (1.02 g, 41 mmol) and iodine (5.3 g, 21 mmol) in ether and added, via cannula, to N-[4-(tert- butyldimethylsilanyloxy)-2-(S)(3 ,4-dichlorophenyl)butyl] -3 -cyano-2-methoxybenzamide (8.2 g, 16.2 mmol) dissolved in 20 mL dry benzene.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002531108A JP2004509954A (en) | 2000-09-28 | 2001-09-27 | Cyclized benzamide neurokinin antagonists for therapeutic use |
US10/381,755 US6924277B2 (en) | 2000-09-28 | 2001-09-27 | Cyclized benzamide neurokinin antagonists for use in therapy |
DE60129829T DE60129829T2 (en) | 2000-09-28 | 2001-09-27 | CYCLED BENZAMIDE NEUROKININE ANTAGONISTS FOR USE IN THERAPY |
EP01970480A EP1324992B1 (en) | 2000-09-28 | 2001-09-27 | Cyclized benzamide neurokinin antagonists for use in therapy |
AU2001290480A AU2001290480A1 (en) | 2000-09-28 | 2001-09-27 | Cyclized benzamide neurokinin antagonists for use in therapy |
US11/115,572 US20050192318A1 (en) | 2000-09-28 | 2005-04-27 | Compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0003476-9 | 2000-09-28 | ||
SE0003476A SE0003476D0 (en) | 2000-09-28 | 2000-09-28 | Compounds |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/115,572 Continuation US20050192318A1 (en) | 2000-09-28 | 2005-04-27 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002026724A1 true WO2002026724A1 (en) | 2002-04-04 |
Family
ID=20281199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2001/002100 WO2002026724A1 (en) | 2000-09-28 | 2001-09-27 | Cyclized benzamide neurokinin antagonists for use in therapy |
Country Status (9)
Country | Link |
---|---|
US (2) | US6924277B2 (en) |
EP (1) | EP1324992B1 (en) |
JP (1) | JP2004509954A (en) |
AT (1) | ATE369348T1 (en) |
AU (1) | AU2001290480A1 (en) |
DE (1) | DE60129829T2 (en) |
ES (1) | ES2288988T3 (en) |
SE (1) | SE0003476D0 (en) |
WO (1) | WO2002026724A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
WO2013004766A1 (en) | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
WO2012173682A3 (en) * | 2011-03-29 | 2013-03-14 | The Broad Institute, Inc. | Compounds and methods for the treatment of isocitrate dehydrognase related diseases |
US9606114B2 (en) | 2004-08-05 | 2017-03-28 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Multivalent chelators containing a scaffold structure for modifying and organizing of target molecules |
US10124010B2 (en) | 2012-10-12 | 2018-11-13 | Mindimmune Therapeutics, Inc. | Cyclic amines |
WO2019162519A1 (en) | 2018-02-26 | 2019-08-29 | Ospedale San Raffaele S.R.L. | Nk-1 antagonists for use in the treatment of ocular pain |
WO2019216795A1 (en) | 2018-05-11 | 2019-11-14 | Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" | Novel modulator of metabotropic and ionotropic transmembrane receptors and use thereof |
WO2021180885A1 (en) | 2020-03-11 | 2021-09-16 | Ospedale San Raffaele S.R.L. | Treatment of stem cell deficiency |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060030556A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
WO2012061754A2 (en) * | 2010-11-05 | 2012-05-10 | The Broad Institute, Inc. | Compounds and methods for treating autoimmune diseases |
TWI598325B (en) * | 2012-10-12 | 2017-09-11 | H 朗德貝克公司 | Benzamides |
CA3234312A1 (en) * | 2021-09-30 | 2023-04-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Four-membered fused cyclic compound and preparation method and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525600A (en) * | 1994-11-28 | 1996-06-11 | American Home Products Corporation | (Thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides |
US5541179A (en) * | 1995-05-02 | 1996-07-30 | American Home Products Corporation | Tropon-2-one piperazine carboxamides as serotonergic agents |
WO1996028158A1 (en) * | 1995-03-14 | 1996-09-19 | Pfizer Limited | Benzamide derivative for treating incontinence |
US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
US5998439A (en) * | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
WO2000064423A2 (en) * | 1999-04-27 | 2000-11-02 | Sanofi-Synthelabo | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2935541B2 (en) * | 1990-06-28 | 1999-08-16 | サントリー株式会社 | Fused heterocyclic compound |
GB9922521D0 (en) * | 1998-10-07 | 1999-11-24 | Zeneca Ltd | Compounds |
ATE400563T1 (en) * | 2000-04-06 | 2008-07-15 | Astrazeneca Ab | NEW NEUROKININ ANTAGONISTS FOR USE AS MEDICINAL PRODUCTS |
-
2000
- 2000-09-28 SE SE0003476A patent/SE0003476D0/en unknown
-
2001
- 2001-09-27 AU AU2001290480A patent/AU2001290480A1/en not_active Abandoned
- 2001-09-27 AT AT01970480T patent/ATE369348T1/en not_active IP Right Cessation
- 2001-09-27 EP EP01970480A patent/EP1324992B1/en not_active Expired - Lifetime
- 2001-09-27 JP JP2002531108A patent/JP2004509954A/en active Pending
- 2001-09-27 WO PCT/SE2001/002100 patent/WO2002026724A1/en active IP Right Grant
- 2001-09-27 DE DE60129829T patent/DE60129829T2/en not_active Expired - Fee Related
- 2001-09-27 US US10/381,755 patent/US6924277B2/en not_active Expired - Fee Related
- 2001-09-27 ES ES01970480T patent/ES2288988T3/en not_active Expired - Lifetime
-
2005
- 2005-04-27 US US11/115,572 patent/US20050192318A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525600A (en) * | 1994-11-28 | 1996-06-11 | American Home Products Corporation | (Thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides |
WO1996028158A1 (en) * | 1995-03-14 | 1996-09-19 | Pfizer Limited | Benzamide derivative for treating incontinence |
US5541179A (en) * | 1995-05-02 | 1996-07-30 | American Home Products Corporation | Tropon-2-one piperazine carboxamides as serotonergic agents |
US5998439A (en) * | 1996-02-21 | 1999-12-07 | Hoescht Marion Roussel, Inc. | Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases |
US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
WO2000064423A2 (en) * | 1999-04-27 | 2000-11-02 | Sanofi-Synthelabo | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
Non-Patent Citations (6)
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006013205A1 (en) * | 2004-08-04 | 2006-02-09 | Solvay Pharmaceuticals B.V. | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation |
US9606114B2 (en) | 2004-08-05 | 2017-03-28 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Multivalent chelators containing a scaffold structure for modifying and organizing of target molecules |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
WO2012173682A3 (en) * | 2011-03-29 | 2013-03-14 | The Broad Institute, Inc. | Compounds and methods for the treatment of isocitrate dehydrognase related diseases |
US9120810B2 (en) | 2011-03-29 | 2015-09-01 | The Board Institute, Inc. | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases |
WO2013004766A1 (en) | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
US10124010B2 (en) | 2012-10-12 | 2018-11-13 | Mindimmune Therapeutics, Inc. | Cyclic amines |
WO2019162519A1 (en) | 2018-02-26 | 2019-08-29 | Ospedale San Raffaele S.R.L. | Nk-1 antagonists for use in the treatment of ocular pain |
EP4371613A2 (en) | 2018-02-26 | 2024-05-22 | Ospedale San Raffaele S.r.l. | Compounds for use in the treatment of ocular pain |
WO2019216795A1 (en) | 2018-05-11 | 2019-11-14 | Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" | Novel modulator of metabotropic and ionotropic transmembrane receptors and use thereof |
WO2021180885A1 (en) | 2020-03-11 | 2021-09-16 | Ospedale San Raffaele S.R.L. | Treatment of stem cell deficiency |
Also Published As
Publication number | Publication date |
---|---|
EP1324992A1 (en) | 2003-07-09 |
US20040029850A1 (en) | 2004-02-12 |
JP2004509954A (en) | 2004-04-02 |
EP1324992B1 (en) | 2007-08-08 |
SE0003476D0 (en) | 2000-09-28 |
AU2001290480A1 (en) | 2002-04-08 |
DE60129829D1 (en) | 2007-09-20 |
US20050192318A1 (en) | 2005-09-01 |
US6924277B2 (en) | 2005-08-02 |
ATE369348T1 (en) | 2007-08-15 |
DE60129829T2 (en) | 2008-04-30 |
ES2288988T3 (en) | 2008-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050192318A1 (en) | Compounds | |
JPH08208606A (en) | Compound for medical treatment | |
JP2010529117A (en) | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators | |
US6500818B1 (en) | Naphthalenecarboxamides as tachykinin receptor antagonists | |
JP2000500481A (en) | 3- (4-Substituted-piperidinyl-1) -1- (3,4-dichlorophenyl) propyl carbamates and ureas and derivatives as novel neurokinin antagonists | |
EP1276729B1 (en) | New neurokinin antagonists for use as medicaments | |
EP1307425B1 (en) | Novel n-(2-phenyl-3-aminopropyl)naphtamides | |
EP1278719B1 (en) | Naphthamide neurokinin antagonists for use as medicaments | |
EP1345899B1 (en) | N-substituted amides as NK1 receptor antagonists | |
US6903092B2 (en) | Naphthamide neurokinin antagonists for use as medicaments | |
US7235541B2 (en) | Neurokinin antagonists for use as medicaments | |
ZA200102658B (en) | Naphthalenecarboxamides as tachykinin receptor antagonists. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001970480 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10381755 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002531108 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001970480 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001970480 Country of ref document: EP |